Dr. Brenda Fitzgerald, director of the U.S. Centers for Disease
Control and Prevention, held "certain complex financial interests"
that she could not sell in time, forcing her to recuse herself from
many public health duties, a Department of Health and Human Services
statement said on Wednesday.
A physician and former commissioner of the Georgia Department of
Public Health, Fitzgerald is the second high-profile health official
in the year-old Republican Trump administration to leave over
financial and ethical questions.
She leaves as the country is dealing with its worst flu season in
years.
Dr. Anne Schuchat, CDC principal deputy director with 30 years at
the agency, will take over until a new director is named, the CDC
said in a statement. Schuchat is a former acting CDC director.
Politico reported on Tuesday that Fitzgerald had traded in tobacco
and healthcare stocks a month after Congress confirmed her
appointment by Trump in July. Her financial disclosure report,
released by Politico, showed she made purchases last August in
shares of Japan Tobacco Inc, Merck & Co Inc, Humana Inc as well as
ADRs of German drugmaker Bayer AG.
The White House declined comment and referred questions to the
Health and Human Services Department.
Democratic U.S. Senator Patty Murray has repeatedly raised concerns
about stock holdings which she said had interfered with Fitzgerald's
ability to advise on public health issues including cancer and the
opioid epidemic.
[to top of second column] |
"It is unacceptable that the person responsible for leading our
nation’s public health efforts has, for months, been unable to fully
engage in the critical work she was appointed to do," Murray said in
a statement on Wednesday.
In December, Murray, the ranking Democrat on the Senate committee
which oversees the CDC, urged Fitzgerald to resolve ongoing
conflicts of interest. Murray said Fitzgerald's conflicts had forced
her to send deputies to testify at congressional hearings on the
opioid crisis.
Last September, Trump's first HHS secretary, former U.S.
Representative Tom Price, resigned over his use of expensive
taxpayer-funded private charter jets for government travel.
Murray said she hoped the newly confirmed HHS Secretary Alex Azar
would encourage the president to choose a new director "who is truly
prepared to focus on families and communities.”
Flu experts cheered the return of Schuchat, who played a leading
role in the U.S. response to the 2009 H1N1 swine flu pandemic.
"I don't have the ear of the president, but if I did, I would say
two words: Anne Schuchat," said Dr. William Schaffner of Vanderbilt
University Medical Center in Nashville, who would like to see
Schuchat as the next CDC director. "She would have the immediate
confidence of all of us in the infectious disease and public health
community."
(Reporting by Julie Steenhuysen in Chicago; Additional reporting by
Ankur Banerjee in Bengaluru and Roberta Rampton in Washington;
Editing by Jeffrey Benkoe and Howard Goller)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |